In the Boardroom
Refine Search
Biotechnology
US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Mirai Bio has announced the appointment of Jens Vogel as the company’s president and chief operating officer (COO). 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
Biotechnology
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Biotechnology
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
Biotechnology
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Biotechnology
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Biotechnology
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Biotechnology
US biotech major Biogen revealed it has appointed Daniel Quirk as chief medical officer and head of medical affairs. 29 October 2024
Biotechnology
AAVantgarde has announced the appointment of Lauren Kaskiel as chief business officer (CBO). 22 October 2024
Biotechnology
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
Biotechnology
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Biotechnology
Turnstone Biologics has announced a major restructuring of its operations, cutting its workforce by approximately 60%. 14 October 2024
Biotechnology
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Biotechnology
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Biotechnology
Privately-held French biotech focused on providing immuno-therapeutics Biomunex Pharmaceuticals today announces the appointment of Dr Simon Plyte as chief scientific officer (CSO) and as a member of its scientific advisory board. 25 April 2022
Biotechnology
Cancer-focused cell therapy company ImmPACT Bio USA today announced the appointment of Venkata Yepuri as chief operating officer. In this role, Mr Yepuri will oversee business operations across the company. 20 April 2022
Biotechnology
Biotech funder and incubator Flagship Pioneering today announced that Michael Severino is joining the company as chief executive (CEO)-partner. 13 April 2022
Biotechnology
Swiss rare diseases specialist Santhera Pharmaceuticals has appointed Shabir Hasham as chief medical officer (CMO) and a member of its executive management team, effective May 1. 13 April 2022
Biotechnology
Norwegian biopharma BerGenBio has appointed experienced oncologist Cristina Oliva as chief medical officer. 11 April 2022
Biotechnology
California-based biotech Eikon Therapeutics announced the appointment of Kenneth Frazier as an independent director effective April 1, 2022. 1 April 2022
Biotechnology
Alector, a Californian company pursuing an immunological approach to targeting neurological conditions, has appointed a new chief medical officer. 30 March 2022
Biotechnology
Japanese firm Sosei Heptares has revealed a new leadership team following a shareholders’ meeting. 24 March 2022
Biotechnology
Californian gene specialist Mammoth Biosciences, a three-year old biotech focused on developing CRISPR products, has made a new senior executive appointment. 24 March 2022
Biotechnology
Arenaviral immunotherapies company Hookipa Pharma has announced that Klaus Orlinger has been promoted to the role of chief scientific officer (CSO). 23 March 2022
Biotechnology
Metagenomi, a California, USA-based genetic medicines company with a versatile portfolio of next-generation gene editing tools, today announced the appointment of Christine Foster, as chief business officer and Alan Cohen, as chief medical officer and senior vice president of Monogenic Diseases. 15 March 2022
Biotechnology
Privately-held US biotech Teon Therapeutics has announced the appointment of Serge Messerlian as chief executive and member of the board of directors. 9 March 2022
Biotechnology
California, USA-based clinical-stage biotech CODA Biotherapeutics, which is focussed on neurological disorders, has appointed Susan Catalano as chief scientific officer. 9 March 2022
Biotechnology
UK and USA-based clinical-stage biopharmaceutical company F-star Therapeutics has appointed James Sandy as chief development officer (CDO), effective March 1. 2 March 2022
Biotechnology
Spark Therapeutics, fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease that was acquired by Swiss pharma giant Roche (ROG: SIX) in a $4.8 billion deal in 2020, today announced that Ron Philip, Spark’s chief operating officer, will succeed co-founder Jeffrey Marrazzo as chief executive. 23 February 2022
Biotechnology
French immunotherapeutics-focussed biotech firm Transgene has appointed Steven Bloom as vice president, chief business officer with immediate effect. 10 February 2022
Biotechnology
New Jersey-based Outlook Therapeutics, a biopharma company working to develop and launch the first approved ophthalmic formulation of bevacizumab for use in retinal indications, has announced the appointment of Joel Prieve as senior vice president, Commercial Operations. 8 February 2022
Biotechnology
Shares of Finnish clinical-stage biopharma Faron Pharmaceutical were up 4.7% at 254 pence this morning as it announced the appointment of Juho Jalkanen as chief operating officer of the company. 31 January 2022
Biotechnology
UK gene and cell therapy group Oxford Biomedica and US genetic medicines company Homology Medicines have agreed to establish a high-performing, full scope adeno-associated virus (AAV) manufacturing and innovation business in the USA. 28 January 2022
Biotechnology
Replacing its retiring co-founder and chief executive Onno van de Stolpe, Belgium-based biotech Galapagos today announced that industry veteran Paul Stoffels will join the company as CEO effective April 1. 27 January 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze